Oxytocin's Effects on Social Cognition in Autism Explored in Randomized Phase 2 Trial

Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental conditions characterized by persistent deficits in social communication and interaction, alongside restricted, repetitive patterns of behavior, interests, or activities. These core symptoms often lead to significant impairments in daily functioning and quality of life. A common comorbidity, intellectual disability, can further exacerbate behavioral challenges, making interventions more complex. Current therapeutic approaches for ASD primarily involve behavioral and educational strategies, with pharmacological treatments largely targeting co-occurring symptoms like irritability or anxiety, rather than the core social deficits. The oxytocin (OXT) system plays a crucial role in regulating social behaviors, including empathy, trust, and bonding, across various species. Dysregulation of this neuropeptide system has been strongly implicated in the pathophysiology of ASD, suggesting that modulating OXT signaling could offer a novel therapeutic strategy. This trial specifically addresses the gap in pharmacological interventions for improving social cognition, a fundamental challenge for individuals with ASD.